Monthly Update: Oncologic, Endocrine & Metabolic: What's new about new tubulin/microtubules binding agents?

References

• LOPES NM, YOUNG ND, MILLER HP, ABRAHAM I, BHLTYAN BK: Utilization of microtitre assays to screen for micro-tubule stabilizers. Proc. Am. Ass. Cancer Res. (1995) 36:303 (Abstr. 1805).
   Google Scholar
• LEUNG KH: A rapid filtration assay for detection of taxol,a novel anti-cancer drug. Proc. Am. Ass. Cancer Res. (1995) 36:306 (Abstr. 1819).
   Google Scholar
• BOLLAG DM, MCQUENEY PA, ZHU J, LAZARIDES E, HEN-SENS 0, KOUPAL L, LIESCH J, GOETZ M, WOODS C: Epothilone, a new structural class of rakrotubuk stabi-lizer. Proc. Am. Ass. Cancer Res. (1995) 36:454 (Abstr. 2711).
   Google Scholar
• BOLLAG DM, MCQUENEY PA, ZHU J, HENSENS 0, KOUPAL L, L1ESCH J, GOETZ M, LAZARIDES E, WOODS CM: Epothi-lones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. CancerRes. (1995) 55:2325–2333.
   Web of Science ®Google Scholar
• SCHIBLER MJ, CABRAL F: Taxol-dependent mutants of Chinese hamster ovary cells with alterations in a- and p-tubtilin.i. Cell Biol. (1986) 102:1522–1531.
   Web of Science ®Google Scholar
• ABRAHAM I, WOLF CL, SAMPSON KE, LABORDE AL, SHELLY JA, ARISTOFF PA, SKULNICK HI: K252a, KT5720, KT 5926 and U98017 support Paclitaxel (Taxol)-depend-ent cells and synergize with PaclitaxeL CancerRes. (1994) 54:5889-5894.
   Google Scholar
• MILLER FR LABORDE AL, SHELLY JA, OLSEN MK, SAMP-SON KE, MCGOVERN JP, PITTS TW, MARSHALL VP, ABRA-HAM 1: Results of a high volume screen for nontaxane microtubuk stabilizers. Proc. Am. Ass. Cancer Res. (1995) 36:304 (Abstr. 1806).
   Google Scholar
• LABORDE AL, SHELLY JA, MIJ.T.FR HR, OLSEN MK, SAMP-SON KE, MCGOVERN JP, LOPES NM, PITTS TW, MARSHALL VP, WHALEY HA, WILEY VH, LI GP, ABRAHAM I: Aria-teromycin, like paclitaxel, supports growth of padi-taxel dependent cells. Proc. Am. Ass. Cancer Res. (1995) 36:304 (Abstr. 1807).
   Google Scholar
• WEINSTEIN JN, KOHN KW, GREVER MR, VISWANADHANVN, RUBINSTEIN LV, MONKS AP, SCUDIERO DA, WELCH L, KOUTSOUKOS AD, CH1AUSA AJ, PAULL KD: Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 258:447–451.
   PubMed Web of Science ®Google Scholar
• HAMEL E: Natural products which interact with tubulinIn the vines domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmac. Ther. (1992) 55:31–51.
   PubMed Web of Science ®Google Scholar
• COCCHIARO C, NELSON C, DE ARRUDA M, PERRON D. WEIFY, HAUPT A, JANSSEN B, BARLOZZARI T: In vitro cyto-toxicity and mechanism of action of LU103793. Proc. Am. Ass. Cancer Res. (1995) 36:391 (Abstr. 2333).
   Google Scholar
• VILLALONA-CALERO M, DEGEN D, BARLOZZARI T, VONHOFF D: LU103793: evaluation by human tumor clono-genic assay of a novel dolastatin. Proc. Am. Ass. Cancer Res. (1995) 36:394 (Abstr. 2349).
   Google Scholar
• SMITH P, NELSON C, JANSSEN B, HAUPT A, BARLOZZARIT: Pre-clinical anti-tumor activity of a novel water-sol-uble Dolastatin 15 analog (LU103793). Proc. Am. Ass. Cancer Res. (1995) 36:393 (Abstr. 2345).
   Google Scholar
• SMITH P, NELSON C, SPIGELMAN M, ROBINSON S, BAR-LOZZARI T: In vitro anti-tumor activity of LU103793: evidence for schedule dependency in MX-1, KB3-1 and P388 tumor models. Proc. Am. Ass. Cancer Res. (1995) 36:394 (Abstr. 2348).
   Google Scholar
• KOYANAGI N, NAGASU T, FUJITA F, WATANABE T, TSUKAHARA K, FUNAHASHI Y, FUJITA M, TAGUCHI T, YOSHINO H, KITOH K: In vivo tumor growth inhibition produced by a novel sulfonamitle, E7010, against ro-dent and human tumors. Cancer Res. (1994) 54:1702–1706.
   PubMed Web of Science ®Google Scholar
• UEDA N, TSUKAHARA N, WATANABE T, HANEDA T, KO-TAKE Y, NIIJIMA J, NAGASU T, YOSHIMATSU K, YOSHINO H, KOYANAGI N, KITOH K: ER-34410, a structurally novel sulfonamide as a potential, injectable antitumor agent. Proc. Am. Ass. Cancer Res. (1995)36:384 (Abstr. 2290).
   Google Scholar
• SMITH CD, ZHANG X, MOOBERRY SL, PA11ERSON GML,MOORE RE: Cryptophycin: anew antimicrotubule agent active against drug-resistant cells. Cancer Res. (1994) 54:3779–3784.
   PubMed Web of Science ®Google Scholar
• VALERIOTE FA, DEMCHIK LL, HELTZEL CE, CORBETT TH,MOORE RE, OGINO J., PATTERSON GML, TRIMURTULU G: Anticancer activity of cryptophycin analogs. Proc. Am. Ass. Cancer Res. (1995) 36:303 (Abstr. 1802).
   Google Scholar
• DEMCHIK LL, CORBETI"M, POLIN L, KUSHNER J, MOORER, LORUSSO PM, VALERIOTE F: Preclinical antitumor activity of Cryptophycin A. Proc. Am. Ass. Cancer Res. (1995) 36:389 (Abstr. 2317).
   Google Scholar
• AICHER TD, BUSZEK KR, FANG FG, FORSYTH CJ, JUNG SH,KISHI Y, MATELICH MC, SCOLA PM, SPERO DM, YOON SK: Total synthesis of Halichondrin B and Norhalichondrin B. J. Am. Chem. Soc. (1992) 114:3162–3164.
   Web of Science ®Google Scholar
• TWOLE MJ, AALFS KK, BUDROW JA, KISHI Y, LITTLEFIELDBA: In vitro and in vivo anticancer properties and cell cycle effects of synthetic halichondrin B. Proc. Am. Ass. Cancer Res. (1995) 36:393 (Abstr. 2342).
   Google Scholar
• GERWICK WH, PROTEAU PJ, NAGLE DG, HAMEL E, BLOK-HIN A, SLATE DL: Structure of Curacin A, a novel antimi-totic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterhun Lyngbya ma-fuscula . J. Org. Chem. (1994) 59:1243–1245.
   Web of Science ®Google Scholar
• BLOKHIN A, NAGLE D, YO0 H, GERWICK W, HAMEL E: Mechanism of binding of curacin A in the colchicine site of tubulin and initial analog studies. Proc. Am. Ass. Cancer Res. (1995) 36:456 (Abstr. 2719).
   Google Scholar
• PACK A, JORDAN MA, GERWICK W, JACOBS RS, WILSON L: Curacin A, a new potent antimitotic marine natural product, increases dynamic instability of microtubules. Proc. Am. Ass. Cancer Res. (1995) 36:455 (Abstr. 2717).
   Google Scholar